




Instance: composition-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: CompositionUvEpi
Title: "Composition for nilemdo Package Leaflet"
Description:  "Composition for nilemdo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp361f3057a7a6d5b08aeb830071bae262)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nilemdo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Nilemdo is and what it is used for </li>
<li>What you need to know before you take Nilemdo </li>
<li>How to take Nilemdo </li>
<li>Possible side effects </li>
<li>How to store Nilemdo </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What nilemdo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nilemdo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Nilemdo is and how it works </p>
<p>Nilemdo is a medicine that lowers levels of  bad  cholesterol (also called  LDL-cholesterol ), a type 
of fat, in the blood. </p>
<p>Nilemdo contains the active substance bempedoic acid, which is inactive until it enters the liver where 
it is changed to its active form. Bempedoic acid decreases the production of cholesterol in the liver and 
increases the removal of LDL-cholesterol from the blood by blocking an enzyme (ATP citrate lyase) 
needed for the production of cholesterol. </p>
<p>What Nilemdo is used for </p>
<p>Nilemdo is given to adults with primary hypercholesterolaemia or mixed dyslipidaemia, which are 
conditions that cause a high cholesterol level in the blood. It is given in addition to a cholesterol-
lowering diet. </p>
<p>Nilemdo is given: 
* if you have been using a statin (such as simvastatin, a commonly used medicine that treats high 
cholesterol) and this does not lower your LDL-cholesterol sufficiently; 
* alone or together with other cholesterol-lowering medicines when statins are not tolerated or 
cannot be used. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Nilemdo: </p>
<ul>
<li>if you are allergic to bempedoic acid or any of the other ingredients of this medicine (listed in 
section 6); </li>
<li>if you are pregnant; </li>
<li>if you are breast-feeding; </li>
<li>if you take more than 40 mg of simvastatin daily (another medicine used to lower cholesterol). </li>
</ul>
<p>Warnings and precautions </p>
<p>Talk to your doctor or pharmacist before taking Nilemdo: 
* if you ever had gout; 
* if you have severe kidney problems; 
* if you have severe liver problems. </p>
<p>Your doctor may do a blood test before you start taking Nilemdo. This is to check how well your liver 
is working. </p>
<p>Children and adolescents </p>
<p>Do not give Nilemdo to children and adolescents under 18 years of age. The use of Nilemdo has not 
been studied in this age group. </p>
<p>Other medicines and Nilemdo </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. In particular, tell your doctor if you are taking medicine(s) with any of the following active 
substances: 
* atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin (used to lower 
cholesterol and known as statins). 
The risk of muscle disease may increase when taking both a statin and Nilemdo. Tell your 
doctor immediately about any unexplained muscle pain, tenderness or weakness. 
* bosentan (used to manage a condition called pulmonary artery hypertension). 
* fimasartan (used to treat high blood pressure and heart failure). 
* asunaprevir, glecaprevir, grazoprevir, voxilaprevir (used to treat hepatitis C). </p>
<p>Pregnancy and breast-feeding </p>
<p>Do not take this medicine if you are pregnant, trying to get pregnant, or think you may be pregnant, as 
there is a possibility that it could harm an unborn baby. If you get pregnant while taking this medicine, 
call your doctor immediately and stop taking Nilemdo. </p>
<ul>
<li>Pregnancy 
Before starting treatment, you should confirm you are not pregnant and are using effective 
contraception, as advised by your doctor. If you use contraceptive pills and suffer from an 
episode of diarrhoea or vomiting that lasts more than 2 days, you must use an alternative method 
of contraception (e.g. condoms, diaphragm) for 7 days following resolution of symptoms. </li>
</ul>
<p>If, after you have started treatment with Nilemdo, you decide that you would like to become 
pregnant, tell your doctor, as your treatment will need to be changed. </p>
<ul>
<li>Breast-feeding 
Do not take Nilemdo if you are breast-feeding because it is not known if Nilemdo passes into 
milk. 
Driving and using machines </li>
</ul>
<p>Nilemdo has no or little influence on the ability to drive and use machines. </p>
<p>Nilemdo contains lactose and sodium </p>
<p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is one tablet once daily. </p>
<p>Swallow the tablet whole with food or between meals. </p>
<p>If you take more Nilemdo than you should </p>
<p>Contact your doctor or pharmacist immediately. </p>
<p>If you forget to take Nilemdo </p>
<p>If you notice that you forgot: 
* a dose late in a day, take the missed dose and take the next dose at your regular time the next 
day. 
* the previous day s dose, take your tablet at the regular time and do not make up for the forgotten 
dose. </p>
<p>If you stop taking Nilemdo </p>
<p>Do not stop taking Nilemdo without your doctor s permission as your cholesterol may rise again. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Side effects can occur with the following frequencies: </p>
<p>Common (may affect up to 1 in 10 people) 
* lower number of red blood cells (anaemia) 
* increased levels of uric acid in blood, gout 
* pain in shoulders, legs, or arms 
* blood test results indicating liver abnormalities </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* decreased haemoglobin (a protein in red blood cells that carries oxygen) 
* raised creatinine and blood urea nitrogen (laboratory tests of kidney function) 
* decreased glomerular filtration rate (a measure of how well your kidneys are working) </p>
<p>Reporting of side effects </p>
<p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The 
expiry date refers to the last day of the month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Nilemdo contains </p>
<ul>
<li>The active substance is bempedoic acid. Each film-coated tablet contains 180 mg of bempedoic 
acid. </li>
<li>
<p>The other ingredients are:</p>
</li>
<li>
<p>lactose monohydrate (see end of section 2 under  Nilemdo contains lactose and sodium ) </p>
</li>
<li>microcrystalline cellulose (E460) </li>
<li>sodium starch glycolate (Type A grade) (see end of section 2 under  Nilemdo contains 
lactose and sodium ) </li>
<li>hydroxypropyl cellulose (E463) </li>
<li>magnesium stearate (E470b) </li>
<li>silica, colloidal anhydrous (E551) </li>
<li>partially hydrolysed poly(vinyl alcohol) (E1203), talc (E553b), titanium dioxide (E171), 
macrogol/PEG (E1521) </li>
</ul>
<p>What Nilemdo looks like and contents of the pack </p>
<p>Film-coated tablets are white to off-white, oval, debossed with  180  on one side and  ESP  on the 
other side. Tablet dimensions: 13.97 mm   6.60 mm   4.80 mm. </p>
<p>Nilemdo is supplied in plastic/aluminium blisters in cartons of 10, 14, 28, 30, 84, 90, 98 or 100 film-
coated tablets or unit dose blisters in cartons of 10 x 1, 50 x 1 or 100 x 1 film-coated tablets. </p>
<p>Not all pack sizes may be marketed in your country. </p>
<p>Marketing Authorisation Holder </p>
<p>Daiichi Sankyo Europe GmbH 
Zielstattstrasse 81379 Munich 
Germany </p>
<p>Manufacturer </p>
<p>Daiichi Sankyo Europe GmbH 
Luitpoldstrasse 1 
85276 Pfaffenhofen 
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Daiichi Sankyo Belgium N.V.-S.A 
T l/Tel: +32-(0) 2 227 18 Lietuva 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 </p>
<p>Daiichi Sankyo Europe GmbH 
 .: +49-(0) 89 7808 0 
Luxembourg/Luxemburg 
Daiichi Sankyo Belgium N.V.-S.A 
T l/Tel: +32-(0) 2 227 18  esk  republika 
Zentiva, k.s. 
Tel: +420 267 241 Magyarorsz g 
Daiichi Sankyo Europe GmbH 
Tel.: +49-(0) 89 7808 0 
Danmark 
Daiichi Sankyo Europe GmbH 
Tlf: +49-(0) 89 7808 0 
Malta 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Deutschland 
Daiichi Sankyo Deutschland GmbH 
Tel: +49-(0) 89 7808 0 
Nederland 
Daiichi Sankyo Nederland B.V. 
Tel: +31-(0) 20 4 07 20 Eesti 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Norge 
Daiichi Sankyo Europe GmbH 
Tlf: +49-(0) 89 7808 0 </p>
<p>Daiichi Sankyo Europe GmbH 
 : +49-(0) 89 7808 0 
 sterreich 
Daiichi Sankyo Austria GmbH 
Tel: +43 (0) 1 485 86 42 0 
Espa a 
Daiichi Sankyo Espa a, S.A. 
Tel: +34 91 539 99 Polska 
Daiichi Sankyo Europe GmbH 
Tel.: +49-(0) 89 7808 0 
France 
Daiichi Sankyo France S.A.S. 
T l: +33 (0) 1 55 62 14 Portugal 
Daiichi Sankyo Portugal, Unip. LDA 
Tel: +351 21 4232Hrvatska 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Rom nia 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Ireland 
Daiichi Sankyo Ireland Ltd 
Tel: +353-(0) 1 489 3Slovenija 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
 sland 
Daiichi Sankyo Europe GmbH 
S mi: +49-(0) 89 7808 0 
Slovensk  republika 
Zentiva, a.s. 
Tel: +421 2 3918 3Italia 
Daiichi Sankyo Italia S.p.A. 
Tel: +39-06 85 2Suomi/Finland 
Daiichi Sankyo Europe GmbH 
Puh/Tel: +49-(0) 89 7808 0 </p>
<p>Daiichi Sankyo Europe GmbH 
 : +49-(0) 89 7808 0 
Sverige 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Latvija 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
United Kingdom (Northern Ireland) 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 </p>
<p>This leaflet was last revised in {month YYYY}. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: CompositionUvEpi
Title: "Composition for nilemdo Package Leaflet"
Description:  "Composition for nilemdo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp361f3057a7a6d5b08aeb830071bae262)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nilemdo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Nilemdo </li>
<li>Sådan skal du tage Nilemdo </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What nilemdo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nilemdo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Nilemdo, og hvordan virker det? </p>
<p>Nilemdo er et lægemiddel, der sænker niveauet af det såkaldt "dårlige" kolesterol (LDL-kolesterol), 
der er en type fedt i blodet. </p>
<p>Nilemdo indeholder det aktive stof bempedoinsyre, der først bliver aktivt, når det når leveren, hvor det 
forandres til dets aktive form. Bempedoinsyre sænker produktionen af kolesterol i leveren og øger 
fjernelsen af LDL-kolesterol fra blodet ved at blokere et enzym (ATP-citratlyase), der er nødvendigt 
for dannelsen af kolesterol. </p>
<p>Hvad anvendes Nilemdo til? </p>
<p>Nilemdo gives til voksne med primær hyperkolesterolæmi eller blandet dyslipidæmi, som er 
sygdomme, der forårsager et højt kolesterolniveau i blodet. Nilemdo gives i tillæg til 
kolesterolsænkende diæt. </p>
<p>Nilemdo gives: </p>
<ul>
<li>
<p>hvis du har brugt et statin (f.eks. simvastatin, et almindeligt anvendt lægemiddel til behandling 
af forhøjet kolesterol), uden at det har sænket dit LDL-kolesterol tilstrækkeligt </p>
</li>
<li>
<p>alene eller sammen med andre lipidsænkende midler, når statin ikke tåles eller ikke kan 
anvendes. </p>
</li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Nilemdo: </p>
<ul>
<li>
<p>hvis du er allergisk over for bempedoinsyre eller et af de øvrige indholdsstoffer i Nilemdo 
(angivet i punkt 6) </p>
</li>
<li>
<p>hvis du er gravid </p>
</li>
<li>
<p>hvis du ammer </p>
</li>
<li>
<p>hvis du tager over 40 mg simvastatin dagligt (et andet kolesterolsænkende lægemiddel). </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller apotekspersonalet, før du tager Nilemdo: </p>
<ul>
<li>
<p>hvis du tidligere har haft urinsyregigt </p>
</li>
<li>
<p>hvis du har alvorlige nyreproblemer </p>
</li>
<li>
<p>hvis du har alvorlige leverproblemer. </p>
</li>
</ul>
<p>Lægen vil måske tage en blodprøve, før du begynder at tage Nilemdo, for at se, hvor godt din lever 
fungerer. </p>
<p>Børn og unge </p>
<p>Nilemdo må ikke gives til børn og unge under 18 år. Anvendelse af Nilemdo er ikke undersøgt hos 
denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Nilemdo </p>
<p>Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. Fortæl det især til lægen, hvis du tager 
lægemidler, der indeholder nogen af følgende aktive stoffer: </p>
<ul>
<li>
<p>atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin eller simvastatin (såkaldte 
statiner, der sænker kolesterolniveauet). 
Risikoen for muskelsygdom kan øges ved samtidig anvendelse af et statin og Nilemdo. Sig det 
til lægen med det samme, hvis du oplever uventet smerte, ømhed eller svaghed i musklerne </p>
</li>
<li>
<p>bosentan (til behandling af forhøjet blodtryk i lungearterierne) </p>
</li>
<li>
<p>fimasartan (til behandling af forhøjet blodtryk og hjertesvigt) </p>
</li>
<li>
<p>asunaprevir, glecaprevir, grazoprevir eller voxilaprevir (til behandling af hepatitis C). </p>
</li>
</ul>
<p>Graviditet og amning </p>
<p>Du må ikke tage dette lægemiddel, hvis du er gravid, har mistanke om, at du er gravid, eller 
planlægger at blive gravid, da det muligvis kan være skadeligt for det ufødte barn. Hvis du bliver 
gravid, mens du tager dette lægemiddel, skal du straks kontakte lægen og holde op med at tage 
Nilemdo. </p>
<ul>
<li>Graviditet 
Inden du påbegynder behandling, skal du bekræfte, at du ikke er gravid, og at du bruger sikker 
prævention som anvist af lægen. Hvis du bruger p-piller og oplever diarré eller opkastning, der 
varer mere end 2 dage, skal du bruge en anden præventionsmetode (f.eks. kondom eller pessar) i 
7 dage, efter at symptomerne har fortaget sig. </li>
</ul>
<p>Hvis du efter at være startet på Nilemdo beslutter, at du ønsker at blive gravid, skal du sige det 
til lægen, da din behandling så skal ændres. </p>
<ul>
<li>Amning 
Du må ikke tage Nilemdo, hvis du ammer, da det er ukendt, om Nilemdo udskilles i 
modermælk. </li>
</ul>
<p>Trafik- og arbejdssikkerhed </p>
<p>Nilemdo påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner. </p>
<p>Nilemdo indeholder lactose og natrium </p>
<p>Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er én tablet én gang dagligt. </p>
<p>Tabletten skal synkes hel og kan tages med eller uden mad. </p>
<p>Hvis du har taget for meget Nilemdo </p>
<p>Kontakt lægen eller apotekspersonalet med det samme. </p>
<p>Hvis du har glemt at tage Nilemdo </p>
<p>Hvis du opdager, at du har glemt: </p>
<ul>
<li>
<p>at tage din dosis sent på dagen, skal du tage den glemte dosis og tage den næste dosis på det 
sædvanlige tidspunkt næste dag. </p>
</li>
<li>
<p>at tage din dosis dagen før, skal du tage din nye tablet på det sædvanlige tidspunkt; du må ikke 
tage en dobbeltdosis som erstatning for den glemte dosis. </p>
</li>
</ul>
<p>Hvis du holder op med at tage Nilemdo </p>
<p>Du må ikke holde op med at tage Nilemdo uden lægens godkendelse, da dit kolesterol kan stige igen. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Bivirkninger kan optræde med følgende hyppigheder: </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter) </p>
<ul>
<li>
<p>nedsat antal røde blodlegemer (anæmi) </p>
</li>
<li>
<p>øget urinsyre i blodet, urinsyregigt </p>
</li>
<li>
<p>smerter i skuldre, ben eller arme </p>
</li>
<li>
<p>unormale levertal i blodprøver </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter) </p>
<ul>
<li>
<p>nedsat hæmoglobin (et protein i de røde blodlegemer, der transporterer ilt) </p>
</li>
<li>
<p>forhøjet kreatinin og karbamid i blodet (laboratorietest for nyrefunktion) </p>
</li>
<li>
<p>nedsat glomerulær filtrationshastighed (et mål for nyrefunktionen) </p>
</li>
</ul>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nilemdo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nilemdo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og æsken efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Nilemdo indeholder: </p>
<ul>
<li>
<p>Aktivt stof: bempedoinsyre. Hver filmovertrukket tablet indeholder 180 mg bempedoinsyre. </p>
</li>
<li>
<p>Øvrige indholdsstoffer:</p>
</li>
<li>
<p>lactosemonohydrat (se til sidst i pkt. 2 under "Nilemdo indeholder lactose og natrium") </p>
</li>
<li>mikrokrystallinsk cellulose (E460) </li>
<li>natriumstivelsesglycolat (type A) (se til sidst i pkt. 2 under "Nilemdo indeholder lactose og 
natrium") </li>
<li>hydroxypropylcellulose (E463) </li>
<li>magnesiumstearat (E470b) </li>
<li>vandfri kolloid silica (E551) </li>
<li>delvist hydrolyseret polyvinylalkohol (E1203), talcum (E553b), titandioxid (E171), 
macrogol/PEG (E1521) </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Filmovertrukne tabletter, der er hvide til offwhite, ovale og præget med "180" på den ene side og 
"ESP" på den anden side. Tabletstørrelse: 13,97 mm × 6,60 mm × 4,80 mm. </p>
<p>Nilemdo fås i plast/aluminium-blisters i æsker med 10, 14, 28, 30, 84, 90, 98 eller 100 filmovertrukne 
tabletter eller enkeltdosisblisters i æsker med 10 x 1, 50 x 1 eller 100 x 1 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført i Danmark. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Daiichi Sankyo Europe GmbH 
Zielstattstrasse 81379 München 
Tyskland </p>
<p>Fremstiller </p>
<p>Daiichi Sankyo Europe GmbH 
Luitpoldstrasse 1 
85276 Pfaffenhofen 
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Daiichi Sankyo Belgium N.V.-S.A 
Tél/Tel: +32-(0) 2 227 18 Lietuva 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
България 
Daiichi Sankyo Europe GmbH 
тел.: +49-(0) 89 7808 0 
Luxembourg/Luxemburg 
Daiichi Sankyo Belgium N.V.-S.A 
Tél/Tel: +32-(0) 2 227 18 Česká republika 
Zentiva, k.s. 
Tel: +420 267 241 Magyarország 
Daiichi Sankyo Europe GmbH 
Tel.: +49-(0) 89 7808 0 
Danmark 
Daiichi Sankyo Europe GmbH 
Tlf: +49-(0) 89 7808 0 
Malta 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Deutschland 
Daiichi Sankyo Deutschland GmbH 
Tel: +49-(0) 89 7808 0 
Nederland 
Daiichi Sankyo Nederland B.V. 
Tel: +31-(0) 20 4 07 20 Eesti 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Norge 
Daiichi Sankyo Europe GmbH 
Tlf: +49-(0) 89 7808 0 
Ελλάδα 
Daiichi Sankyo Europe GmbH 
Τηλ: +49-(0) 89 7808 0 
Österreich 
Daiichi Sankyo Austria GmbH 
Tel: +43 (0) 1 485 86 42 0 
España 
Daiichi Sankyo España, S.A. 
Tel: +34 91 539 99 Polska 
Daiichi Sankyo Europe GmbH 
Tel.: +49-(0) 89 7808 0 
France 
Daiichi Sankyo France S.A.S. 
Tél: +33 (0) 1 55 62 14 Portugal 
Daiichi Sankyo Portugal, Unip. LDA 
Tel: +351 21 4232Hrvatska 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
România 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Ireland 
Daiichi Sankyo Ireland Ltd 
Tel: +353-(0) 1 489 3Slovenija 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Ísland 
Daiichi Sankyo Europe GmbH 
Sími: +49-(0) 89 7808 0 
Slovenská republika 
Zentiva, a.s. 
Tel: +421 2 3918 3Italia 
Daiichi Sankyo Italia S.p.A. 
Tel: +39-06 85 2Suomi/Finland 
Daiichi Sankyo Europe GmbH 
Puh/Tel: +49-(0) 89 7808 0 
Κύπρος 
Daiichi Sankyo Europe GmbH 
Τηλ: +49-(0) 89 7808 0 
Sverige 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Latvija 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
United Kingdom (Northern Ireland) 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 </p>
<p>Denne indlægsseddel blev senest ændret {måned ÅÅÅÅ}. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nilemdo Package Leaflet for language en"
Description: "ePI document Bundle for nilemdo Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[0].resource = composition-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[=].resource = mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4
                            
                    
Instance: bundlepackageleaflet-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nilemdo Package Leaflet for language da"
Description: "ePI document Bundle for nilemdo Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[0].resource = composition-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4"
* entry[=].resource = mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4
                            
                    



Instance: mpb0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Nilemdo 180 mg film-coated tablets"
Description: "Nilemdo 180 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/20/1425/001 - 011"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Nilemdo 180 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: b0dbf83dbdd0b6f9d3c0904a5e7ceaa4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "nilemdo"

* status = #current
* mode = #working

* title = "List of all ePIs associated with nilemdo"

* subject = Reference(mp361f3057a7a6d5b08aeb830071bae262)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#nilemdo "nilemdo"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4) // nilemdo en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4) // nilemdo da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-b0dbf83dbdd0b6f9d3c0904a5e7ceaa4
InstanceOf: List

* insert b0dbf83dbdd0b6f9d3c0904a5e7ceaa4ListRuleset
    